Form 4 Filing for Agios Pharmaceuticals, Inc.

This filing details transactions by Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, Inc., on June 18, 2026. Gheuens disposed of 3,000 Performance Share Units (PSUs) and acquired 3,000 Restricted Stock Units (RSUs). The PSUs, representing contingent rights to common stock, were disposed of with a post-transaction balance of 9,000 units. The RSUs, also representing contingent rights to common stock, were acquired, resulting in a post-transaction balance of 3,000 units. Both transactions involved zero price per share, and the underlying security for both is common stock. Footnote F2 clarifies that the performance criteria for the PSUs were met as of June 18, 2026, with vesting scheduled for December 31, 2027, subject to continued service. The filing was signed by William Cook as attorney-in-fact for Sarah Gheuens.